Prolonged use of proton pump inhibitors, CagA status, and the outcome of Helicobacter pylori gastritis

Journal of Clinical Gastroenterology

Volumn 34, Issue 5, 2002, Pages 536-540

  Gudlaugsdottir, Sunna ^a   Van Dekken, Hermann ^a   Stijnen, Theo ^b   Wilson, J H Paul ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

Barrett's esophagus; CagA virulence strain; Gastroesophageal reflux disease; Proton pump inhibitors

Indexed keywords

CAGA PROTEIN; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; ATROPHIC GASTRITIS; BARRETT ESOPHAGUS; CLINICAL ARTICLE; DISEASE CLASSIFICATION; DRUG USE; DYSPEPSIA; FEMALE; GASTRITIS; HELICOBACTER INFECTION; HISTOPATHOLOGY; HUMAN; INTESTINE METAPLASIA; MALE; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; STOMACH BIOPSY;

ANTI-ULCER AGENTS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; GASTRIC MUCOSA; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PROTON PUMPS; TIME FACTORS;

EID: 0036231168     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-200205000-00011     Document Type: Article

References (32)

1. Appropriate acid suppression for the management of gastro-oesophageal reflux disease
2. Acid suppression in the long-term treatment of peptic stricture and Barrett's esophagus
3. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication
4. Helicobacter pylori infection and chronic gastric acid hyposecretion
5. Pathogenesis of esophagitis in patients with gastroesophageal reflux
6. Classification and grading of gastritis. The updated Sydney System
7. Diagnosis of Helicobacter pylori infection by using pylori set EIA-G and EIA-A for detection of serum immunoglobulin G (IgG) and IgA antibodies
8. Factors influencing corpus argyrophil cell density and hyperplasia in reflux esophagitis patients treated with antisecretory drugs and controls
9. Current or recent proton pump inhibitor therapy markedly impairs the accuracy of the [14C]urea breath test
10. Helicobacter pylori infection, chronic gastritis, and proton pump inhibitors
11. IgG antibody titer against Helicobacter pylori correlates with presence of cytotoxin associated gene A-positive H. pylori strains
12. Parasitism by the "slow" bacterium Helicobacter pylori leads to altered gastric homeostasis and neoplasia
13. Hypotheses on the pathogenesis and natural history of Helicobacter pylori-induced inflammation
14. Interaction of Helicobacter pylori and its fatty acids with parietal cells and gastric H+/K(+)-ATPase
15. Cloning and sequencing of the gene encoding an acid inhibitory protein in Helicobacter pylori
16. Interleukin-1 beta and tumor necrosis factor-alpha inhibit aminopyrine accumulation in cultured parietal cells by multiple pathways
17. How does Helicobacter pylori cause mucosal damage? Its effect on acid and gastrin physiology
18. Helicobacter pylori and the risk and management of associated diseases: Gastritis, ulcer disease, atrophic gastritis and gastric cancer
19. Clinical relevance of the CagA, vacA, and iceA status of Helicobacter pylori
20. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease
21. The association of histologic gastritis with gastroesophageal reflux and delayed gastric emptying
22. The prevalence of esophagitis in patients with duodenal ulcer or ulcerlike dyspepsia
23. The risk of stomach cancer in patients with gastric or duodenal ulcer disease
24. Lack of effect of acid suppression therapy on gastric atrophy
25. The phenotype of gastric mucosa coexisting with Barrett's esophagus
26. Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection
27. The interrelationship between cytotoxin-associated gene A, vacuolating cytotoxin, and Helicobacter pylori-related diseases
28. Hypothesis: The changing relationships of Helicobacter pylori and humans: Implications for health and disease
29. Helicobacter pylori augments the pHincreasing effect of omeprazole in patients with duodenal ulcer
30. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis
31. Altered states: Involvement of phosphorylated CagA in the induction of host cellular growth changes by Helicobacter pylori
32. Helicobacter pylori CagA protein can be tyrosine phosphorylated CagA in gastric epithelial cells